丁苯酞对血管性痴呆疗效的Meta分析

发布时间：2018-05-03 19:40

本文选题：丁苯酞 + 血管性痴呆　；参考：《新乡医学院》2017年硕士论文

【摘要】：背景血管性痴呆(vascular dementia,VD)是指脑血管病因素导致的脑组织损害所引起的临床痴呆,是痴呆的常见类型之一,发病率随着脑血管疾病等增高而逐年上升,其严重影响人们的日常生活和生活质量。目前尚无特效的治疗药物。丁苯酞是我国自主研发和生产的Ⅰ类新药,可明显改善脑缺血区域的血流量和微循环,目前广泛应用于急性缺血性脑卒中,但目前丁苯酞对血管性痴呆的疗效的系统评价尚少。目的采用Meta分析的方法来评价丁苯酞治疗血管性痴呆的临床疗效。方法系统检索万方数据库、相关期刊论文、维普中文科技期刊数据库、PubMed数据库、Embase数据库和Ovid数据库,两位研究者独立筛选原始研究,并最终提取有效数据,合并效应量SMD及95%可信区间,应用固定效应模型或随机效应模型来计算,并对其进行异质性分析、敏感性分析及亚组分析。结果最终纳入8个随机对照试验,丁苯酞在改善血管性痴呆患者的简易精神状态检查量表(MMSE)评分上,SMD=0.75,95%CI=(0.59,0.92);改善日常生活能力量表(ADL)评分上,SMD=㧟0.17,95%CI=(㧟0.33,㧟0.01);对其按疗程进行亚组分型,与对照组比较,应用丁苯酞均可改善其MMSE及ADL评分。不良反应方面,其多为头晕、恶心、腹泻等轻微且一过性的,停药后监测血常规、尿常规、肝功能、肾功能、心电图均无明显变化。结论丁苯酞能改善血管性痴呆患者MMSE评分及ADL评分,不良反应较少,其应用于血管性痴呆的治疗有效且相对安全。
[Abstract]:Background: vascular dementia (VD) is a kind of clinical dementia caused by cerebrovascular disease. It is one of the common types of dementia. The incidence of vascular dementia increases with the increase of cerebrovascular disease. It seriously affects people's daily life and quality of life. At present, there are no special therapeutic drugs. Butyphthalide is a class I new drug developed and produced independently in China, which can improve the blood flow and microcirculation in cerebral ischemic area. At present, butyphthalide is widely used in acute ischemic stroke, but there is little systematic evaluation of the curative effect of butyphthalide on vascular dementia. Objective to evaluate the clinical efficacy of butyphthalide in the treatment of vascular dementia by Meta analysis. Methods Wanfang database, full text database of Chinese periodicals, Embase database and Ovid database of Weipu Chinese sci-tech journal database were searched systematically. The two researchers independently screened the original research and finally extracted valid data. The combined effect quantity (SMD) and 95% confidence interval were calculated by fixed effect model or random effect model. The heterogeneity, sensitivity and subgroup analysis were performed. Results in 8 randomized controlled trials, butylphthalide was used to improve the MMSE score of vascular dementia patients. The scores of SMD-0.75 ~ 95CIQ 0.59 ~ 0.92 and ADL were 0.17 ~ 95 ~ 0.33 / 0. 01% respectively, and the subgroups were classified according to the course of treatment. Compared with the control group, butyphthalide could improve the MMSE and ADL scores. The adverse reactions were mostly dizziness, nausea, diarrhea and other mild and transient, after the withdrawal of monitoring blood routine, urine routine, liver function, renal function, electrocardiogram did not significantly change. Conclusion Butylphthalide can improve the MMSE score and ADL score of vascular dementia patients with less adverse reactions. It is effective and relatively safe in the treatment of vascular dementia.
【学位授予单位】：新乡医学院
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R749.13

【参考文献】